Benjamin F. Edwards & Company Inc. Increases Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Benjamin F. Edwards & Company Inc. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,450 shares of the medical equipment provider’s stock after purchasing an additional 338 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Intuitive Surgical were worth $2,870,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of ISRG. Capital Research Global Investors purchased a new stake in Intuitive Surgical in the first quarter valued at approximately $374,390,000. Coatue Management LLC raised its stake in shares of Intuitive Surgical by 65.7% during the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock worth $439,106,000 after acquiring an additional 516,054 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. Edgewood Management LLC raised its stake in shares of Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after acquiring an additional 374,667 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after acquiring an additional 302,382 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. Morgan Stanley lifted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. BTIG Research raised their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Truist Financial raised their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. Finally, JPMorgan Chase & Co. raised their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $446.45.

Insiders Place Their Bets

In other news, Director Amy L. Ladd sold 450 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares in the company, valued at approximately $402,519.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the sale, the director now owns 821 shares of the company’s stock, valued at $402,519.88. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock worth $25,528,753 in the last three months. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Stock Down 0.8 %

Intuitive Surgical stock opened at $486.20 on Friday. The business has a 50-day simple moving average of $468.01 and a two-hundred day simple moving average of $425.12. The company has a market cap of $172.46 billion, a P/E ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 EPS. Research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.